Q-omics provides the consensus-scored E2F3P2 profile across patient tissues and cancer cell-line models. E2F3P2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, E2F3P2 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, E2F3P2 RNA expression shows 16,099 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KICH, THCA, and KIRP as cancer lineages where E2F3P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for E2F3P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes E2F3P2 survival associations across molecular data types. E2F3P2 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible E2F3P2 RNA expression–survival associations across cancer types. High E2F3P2 expression shows unfavorable associations in KICH, LGG, THCA and UVM, but favorable associations in SARC and READ. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for E2F3P2 RNA expression.
This table summarizes E2F3P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for E2F3P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. E2F3P2 shows lower tumor expression in THCA and KICH and higher tumor expression in KIRP, STAD, CHOL and BRCA. The THCA box plot shows higher E2F3P2 RNA expression in normal versus tumor tissue (log2 FC = −0.398, t-test p < 0.001).
This table shows molecular features associated with E2F3P2 in patient tissues and cancer cell lines. In patient samples, E2F3P2 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
